The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium entitled “Advances in Biologics Development and Delivery”.

Catalent Pharma Solutions today announced that two of its scientific experts will present at the International Society for Pharmaceutical Engineering (ISPE) Aseptic Conference.

Catalent Pharma Solutions today announced that Michael Sadick, Ph.D., Principal Scientist, Catalent Biologics, will present at the annual US Bioassay Conference of the BioPharmaceutical Emerging Best Practices Association (BEBPA).

Catalent Pharma Solutions today announced that Cornell Stamoran, Ph.D. will present at the 23rd annual Drug Delivery Partnerships (DDP) conference.

Catalent Pharma Solutions , today announced that one of its scientific experts will present at CASSS’s WCBP conference, the 23rd Symposium on the Interface of Regulatory & Analytical Sciences for Biotechnology Health Products, co-sponsored by the US Food and Drug Administration, at The Mayflower Hotel, Washington, D.C. on Jan. 29 – 31, 2019.

Catalent, Inc. today announced it has commenced a $200 million capital investment in its Biologics business to expand drug substance manufacturing capacity and drug product fill/finish capacity due to projected growth among existing and future customers.

Catalent today announced that following the site’s twentieth commercial product approval, it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, Indiana, biologics manufacturing facility.

Catalent today announced that two of its experts have been invited to speak at the upcoming Waterside Conference.

Catalent today announced that one of its scientific experts will host a workshop during KNect365 Life Sciences’ annual Well Characterized Biologics & Biological Assays conference (WCBBA).